- Home
- MPU vs CELU Comparison
MPU vs CELU Comparison
Compare MPU & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MPU | CELU |
|---|---|---|
| Founded | 1989 | 2016 |
| Country | Singapore | United States |
| Employees | N/A | 123 |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.8M | 36.0M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | MPU | CELU |
|---|---|---|
| Price | $0.73 | $1.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 47.1K | 28.3K |
| Earning Date | 03-09-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $76.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $1.01 |
| 52 Week High | $4.44 | $4.35 |
Technical Indicators
Market Signals| Indicator | MPU | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 43.58 | 51.01 |
| Support Level | $0.72 | $1.25 |
| Resistance Level | $0.81 | $1.33 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 53.54 | 49.15 |
Price Performance
Historical ComparisonAbout MPU Mega Matrix Corp.
Mega Matrix Inc is a holding company. It operates through its two subsidiaries Mega Metaverse Corp (Mega) and JetFleet Management Corp (JMC). The Company has two business segments which are comprised of : ETH staking business and The leasing of regional aircraft to foreign and domestic regional airlines. The majority of the company's revenue is earned through Leasing business segment. The company operates in USA and Canada, Asia-Pacific, Europe, Middle East and Africa, and Latin America.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.